About
Vildagliptin 50mg is an oral antidiabetic medication classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by selectively inhibiting the enzyme DPP-4, which is responsible for the rapid degradation of incretin hormones, such as GLP-1 and GIP. By preserving these endogenous hormones, Vildagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from pancreatic alpha cells. This dual action helps to normalize both fasting and postprandial blood glucose levels, providing effective glycemic control for adults with type 2 diabetes mellitus. It is indicated either as monotherapy when metformin is inappropriate or contraindicated, or in combination with other antidiabetic agents to achieve optimal blood sugar management and reduce the risk of diabetes-related complications.
Uses
- Treatment of type 2 diabetes mellitus.
- Improvement of glycemic control.
- Used as monotherapy when Metformin is inappropriate.
- As an add-on to other antidiabetic medications.
Directions For Use
Take orally, usually once or twice daily, with or without food, as prescribed by your doctor. Do not crush or chew the tablet.
Benefits
- Effective reduction in blood glucose levels.
- Low risk of hypoglycemia when used alone.
- Weight-neutral effect.
- Improves both fasting and post-meal glucose.
- Well-tolerated in most patients.
- Convenient oral administration.
Side Effects
- Headache
- Dizziness
- Nasopharyngitis
- Cough
- Constipation
- Peripheral edema
- Hypoglycemia (especially with sulfonylureas or insulin)
- Skin reactions (e.g., rash)
- Arthralgia
- Pancreatitis (rare)
- Abnormal liver function tests (rare)
- Angioedema (rare)
Safety Measures
- Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may affect blood sugar levels.
- Pregnancy - Not recommended during pregnancy due to insufficient data on human safety. Consult your doctor for alternatives.
- Breastfeeding - Not recommended during breastfeeding as it is unknown if Vildagliptin passes into breast milk.
- Liver - Contraindicated in patients with moderate to severe hepatic impairment (ALT or AST >3x ULN). Use with caution in mild impairment.
- Kidney - Dose adjustment may be required for patients with moderate to severe renal impairment (eGFR <50 mL/min/1.73m²).
- Lung - No specific contraindications related to lung conditions, but general caution applies in severe systemic illness.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!